Banco Bradesco S.A. has announced a strategic initiative to consolidate its extensive healthcare operations into a single publicly listed company, to be named Bradsaúde. The move, disclosed on March 6, 2026, involves merging the bank's health assets under the existing listed entity Odontoprev. The newly formed company is projected to generate approximately 52 billion Brazilian reais in revenue for the 2025 fiscal year.
Strategic Rationale and Market Timing
Bradesco's decision comes as Brazil's capital markets and healthcare sector show signs of recovery. The bank aims to unlock value from its diversified financial and insurance portfolio by creating a more transparent and focused investment vehicle. In regulatory filings, Bradesco highlighted that the streamlined structure will provide investors with clearer insight into the performance of its health and dental segments while enabling broader distribution of its services.
Transaction Structure and Key Steps
The consolidation process is scheduled to commence with an extraordinary shareholder meeting on March 31. The first step involves a partial spin-off of Bradseg Participações, transferring its stakes in Odontoprev and Bradesco Gestão de Saúde (BGS) directly to Banco Bradesco. Subsequently, subject to necessary approvals, Odontoprev will absorb Bradesco Gestão de Saúde. The combined entity will retain its listing on the B3 exchange's Novo Mercado segment, which mandates higher corporate governance standards, and will serve as the primary holding company for all of Bradesco's health-related businesses.
According to company presentations, the merged platform is forecast to achieve a net income of 3.6 billion reais in 2025, with a return on average equity (ROAE) of 23.7%. Chief Executive Officer Marcelo Noronha suggested the new company could command a market valuation between 40 billion and 50 billion reais, leaning toward the upper end of that range.
Comprehensive Healthcare Ecosystem
Bradsaúde is designed to be a full-spectrum healthcare provider, extending far beyond dental coverage. The consolidated entity will encompass Bradesco Saúde, Mediservice, the Novamed clinic network, health-technology firm Orizon, hospitals under Atlântica, and a 25% stake in diagnostic company Fleury. It will also maintain partnership agreements with major hospital networks Rede D’Or and Mater Dei.
Upon completion of the share swap, Banco Bradesco will hold a 91.35% controlling stake in Bradsaúde. Existing Odontoprev shareholders will retain the remaining 8.65% interest. Financial institution Citi has provided a fairness opinion supporting the exchange ratio, and an independent committee at Odontoprev has endorsed the transaction.
Leadership and Financial Profile
Carlos Marinelli, appointed to lead Bradsaúde, emphasized that the company will launch with "zero leverage," meaning it will be entirely free of debt. Ivan Gontijo of Bradesco Seguros clarified that there are no plans to convert the new operation into a closed insurer-hospital system, despite medical cost inflation in Brazil running nearly three times the official IPCA consumer price index.
Chairman Luiz Carlos Trabuco Cappi stated the business has gained "scale, momentum and strategic relevance," and that the previous corporate structure hindered transparency. He characterized Bradsaúde during its presentation as Brazil's "most comprehensive healthcare ecosystem."
Regulatory Hurdles and Future Steps
The ambitious plan still faces several approval milestones before becoming operational. Shareholders of Bradesco, Odontoprev, and Bradesco Gestão de Saúde must all grant their consent. Furthermore, the Agência Nacional de Saúde Suplementar (ANS), Brazil's regulator for private health plans, must also approve the transaction.
A notable point is that Bradsaúde will initially launch with a free float of only 8.65%, significantly below the Novo Mercado's minimum requirement of 25%. This necessitates a future secondary share offering, though the bank has not yet provided a specific timeline for this subsequent capital markets event.
Once established, Bradsaúde will be a significant player in the Brazilian healthcare landscape, serving an estimated 3.9 million health plan beneficiaries and 9.3 million dental plan beneficiaries, with access to over 3,600 contracted hospital beds. Executives have consistently argued that the previous, more fragmented structure obscured the business's value and performance, and that the new standalone company will place it squarely in the investor spotlight.
